4.7 Article

2017 revisions of McDonald criteria shorten the time to diagnosis of multiple sclerosis in clinically isolated syndromes

期刊

JOURNAL OF NEUROLOGY
卷 265, 期 11, 页码 2684-2687

出版社

SPRINGER HEIDELBERG
DOI: 10.1007/s00415-018-9048-8

关键词

Clinically isolated syndrome; Multiple sclerosis; Conversion; Diagnostic criteria; Dissemination in space; Dissemination in time; Symptomatic gadolinium enhancing lesion; Oligoclonal bands

资金

  1. Novartis
  2. Teva
  3. Sanofi Genzyme
  4. Almirall
  5. Associazione Italiana Sclerosi Multipla (AISM)
  6. Genzyme
  7. Bayer Schering
  8. Biogen-Dompe
  9. Boehringer Ingelheim
  10. Lundbeck
  11. Merck-Serono
  12. Sigma-Tau
  13. UCB Pharma
  14. Biogen Idec
  15. Biogen
  16. Merck Serono
  17. Eisai
  18. Sanofi-Aventis
  19. Roche

向作者/读者索取更多资源

Objectives To investigate the impact of the 2017 revisions of McDonald criteria on the diagnosis of multiple sclerosis (MS) in a cohort of patients with clinically isolated syndrome (CIS) and dissemination in space (DIS) of demyelinating lesions. Methods We retrospectively analyzed 137 patients with CIS+DIS from two Italian MS centers. Results Application of the 2017 revisions of McDonald criteria in our cohort led to a diagnosis of MS in 82.5% of the patients who could have not been diagnosed with MS according to the previous criteria at the time of the first demyelinating event. After a follow-up of 3.8 +/- 2.9 years, 85.8% of these patients eventually satisfied also the previous (2010) criteria. Conclusions Application of the 2017 revisions of McDonald criteria results in an earlier diagnosis of MS in a large percentage of CIS patients destined to convert to MS.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据